Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404).
作者信息
Ko Jihee, Moon Sun Joon
机构信息
Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
出版信息
Diabetes Metab J. 2023 Jul;47(4):571-572. doi: 10.4093/dmj.2023.0164. Epub 2023 Jul 27.
Abstract
摘要
相似文献
1
Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404).钠-葡萄糖协同转运蛋白2抑制剂与胰高血糖素样肽-1受体激动剂之间糖尿病视网膜病变的风险（《糖尿病与代谢杂志》2023年；47:394-404）
Diabetes Metab J. 2023 Jul;47(4):571-572. doi: 10.4093/dmj.2023.0164. Epub 2023 Jul 27.
2
Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404).钠-葡萄糖协同转运蛋白2抑制剂与胰高血糖素样肽-1受体激动剂之间糖尿病视网膜病变的风险（《糖尿病代谢杂志》2023年；47:394-404）
Diabetes Metab J. 2023 Jul;47(4):573-574. doi: 10.4093/dmj.2023.0188. Epub 2023 Jul 27.
3
Sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists treatment: variable observations of sequelae on diabetic retinopathy.钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽1受体激动剂治疗：糖尿病视网膜病变后遗症的不同观察结果
J R Soc Med. 2023 Dec;116(12):408. doi: 10.1177/01410768231215999. Epub 2023 Dec 6.
4
Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.钠-葡萄糖共转运蛋白 2 抑制剂与胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病的视网膜病变风险。
Diabetes Metab J. 2023 May;47(3):394-404. doi: 10.4093/dmj.2022.0221. Epub 2023 Mar 6.
5
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.2型糖尿病的一线治疗：使用钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂
Ann Intern Med. 2023 Apr;176(4):eL230007. doi: 10.7326/L23-0007.
6
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.2型糖尿病的一线治疗：使用钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽1受体激动剂
Ann Intern Med. 2023 Apr;176(4):eL230005. doi: 10.7326/L23-0005.
7
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.2型糖尿病的一线治疗：使用钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂
Ann Intern Med. 2023 Apr;176(4):eL230006. doi: 10.7326/L23-0006.
8
How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.SGLT2（钠-葡萄糖共转运蛋白 2）抑制剂和 GLP-1（胰高血糖素样肽-1）受体激动剂如何降低心血管结局？：已完成和正在进行的机制试验。
Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):506-522. doi: 10.1161/ATVBAHA.119.311904. Epub 2020 Jan 30.
9
Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization.胰高血糖素样肽-1 受体激动剂与心力衰竭：进一步生成证据和优化实践指南的必要性。
Circulation. 2020 Sep 22;142(12):1205-1218. doi: 10.1161/CIRCULATIONAHA.120.045888. Epub 2020 Sep 21.
10
Glucagon-Like Peptide 1 Receptor Agonists (GLP1RA) and Sodium-glucose co-transporter-2 inhibitors (SGLT2i): Making a pragmatic choice in diabetes management.胰高血糖素样肽 1 受体激动剂 (GLP1RA) 和钠-葡萄糖共转运蛋白 2 抑制剂 (SGLT2i)：在糖尿病管理中做出务实的选择。
J Pak Med Assoc. 2022 May;72(5):989-990. doi: 10.47391/JPMA.22-64.
本文引用的文献
1
Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.钠-葡萄糖共转运蛋白 2 抑制剂与胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病的视网膜病变风险。
Diabetes Metab J. 2023 May;47(3):394-404. doi: 10.4093/dmj.2022.0221. Epub 2023 Mar 6.
2
Type 2 diabetes.2型糖尿病
Lancet. 2022 Nov 19;400(10365):1803-1820. doi: 10.1016/S0140-6736(22)01655-5. Epub 2022 Nov 1.
3
Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis.钠-葡萄糖协同转运蛋白 2 抑制剂对 2 型糖尿病患者眼部结局的影响：系统评价和荟萃分析。
Diabetes Obes Metab. 2021 Jan;23(1):252-257. doi: 10.1111/dom.14197. Epub 2020 Oct 13.
4
Incidence and progression of diabetic retinopathy: a systematic review.糖尿病视网膜病变的发病和进展：系统评价。
Lancet Diabetes Endocrinol. 2019 Feb;7(2):140-149. doi: 10.1016/S2213-8587(18)30128-1. Epub 2018 Jul 11.
5
Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials.强化血糖控制对 2 型糖尿病患者微血管结局的影响：来自随机对照试验的个体参与者数据的荟萃分析。
Lancet Diabetes Endocrinol. 2017 Jun;5(6):431-437. doi: 10.1016/S2213-8587(17)30104-3. Epub 2017 Mar 30.
6
Current epidemiology of diabetic retinopathy and diabetic macular edema.糖尿病视网膜病变和糖尿病黄斑水肿的当前流行病学。
Curr Diab Rep. 2012 Aug;12(4):346-54. doi: 10.1007/s11892-012-0283-6.
Zotero 插件